注册分类：二类 主要成分：氟雷拉纳 适应症：用于治疗后备鸡、产蛋鸡和种鸡的鸡皮刺螨（红螨）感染。 用法与用量：以本品计。混饮：鸡每 1kg 体重 0.05ml（相当于以氟雷拉纳计 每 1kg 体重 0.5mg），每隔 7 日给药 1 次，连用 2 次。 二、新兽药研究开发情况及相关市场背景情况 证券代码：603566 证券简称：普莱柯 公告编号：2025-020 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及其全资子公司洛阳惠中兽 药有限公司（以下简称"惠中兽药"）等单位联合申报的"氟雷拉纳溶液"为新 兽药，并于 2025 年 4 月 27 日公示了核发《新兽药注册证书》（中华人民共和国 农业农村部公告第 901 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：氟雷拉纳溶液 按照《兽药管理条例》《兽药产品批准文号管理办法》等相关规定，该产品 在上 ...

Investment Rating - The investment rating for the company is "Add" and maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, the first quarter of 2025 showed a recovery with revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The company is facing pressure in the pig vaccine segment due to increased competition, while the poultry vaccine and pharmaceutical segments are showing growth. The pet vaccine segment is also emerging as a new growth area, with sales exceeding 46 million yuan in 2024 [5] - The company is implementing marketing strategy adjustments and organizational changes to strengthen cost control and core competitiveness, anticipating a recovery in performance as the pig vaccine market stabilizes and new growth opportunities in pet vaccines arise [6] Financial Summary - The company’s financial performance is projected to improve from 2025 to 2027, with expected earnings per share (EPS) of 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively. The revenue is expected to grow from 1.131 billion yuan in 2025 to 1.259 billion yuan in 2027, with net profit projected to increase from 169 million yuan to 237 million yuan over the same period [7][9]

Investment Rating - The investment rating for the company is "Add" and it is maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, in Q1 2025, the company showed signs of recovery with a revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The performance of different vaccine products varies significantly, with poultry vaccines showing continuous growth, while pig vaccines are under pressure due to increased competition in the swine breeding industry. The company’s revenue from poultry vaccines and antibodies increased by 3.31% and 33.80% respectively in 2024 and Q1 2025, while revenue from pig vaccines decreased by 22.58% and 11.64% respectively [5] - The company is expected to recover as it adjusts its marketing strategy and implements organizational changes, with projected EPS for 2025-2027 being 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively, maintaining an "Add" rating [6] Company Overview - The latest closing price of the company's stock is 13.70 yuan, with a total market capitalization of 4.7 billion yuan. The company has a total share capital of 346 million shares, with a debt-to-asset ratio of 15.2% and a P/E ratio of 50.74 [3][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.043 billion yuan in 2024, a decrease of 16.77% year-on-year, and a net profit attributable to the parent company of 93 million yuan, down 46.82% [5] - In Q1 2025, the company achieved a revenue of 279 million yuan, an increase of 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% [5] - The company is facing short-term pressure in its piglet business due to intensified industry competition, but is focusing on growth in poultry vaccines and pharmaceuticals, as well as increasing sales in ruminant and pet vaccines [5][6] - The company has adjusted its profit forecasts for 2025-2026 downwards and added a forecast for 2027, expecting net profits of 171 million, 207 million, and 249 million yuan for 2025-2027 respectively [5] Financial Summary - The company's revenue for 2025 is estimated at 1.211 billion yuan, with a year-on-year growth of 16.1% [9] - The gross margin for Q1 2025 is reported at 59.71%, a decrease of 4.70 percentage points, while the net margin is 18.99%, an increase of 7.39 percentage points [7] - R&D expenses for 2024 amounted to 106 million yuan, representing 10.17% of total revenue [7] - The company’s earnings per share (EPS) for 2025 is projected to be 0.49 yuan, with a price-to-earnings (P/E) ratio of 27.7 [9]

农林牧渔/动物保健Ⅱ | 日期 | 2025/4/25 | | --- | --- | | 当前股价(元) | 13.70 | | 一年最高最低(元) | 25.00/10.80 | | 总市值(亿元) | 47.41 | | 流通市值(亿元) | 47.41 | | 总股本(亿股) | 3.46 | | 流通股本(亿股) | 3.46 | | 近 3 个月换手率(%) | 117.46 | 股价走势图 数据来源：聚源 -40% -20% 0% 20% 40% 60% 2024-04 2024-08 2024-12 普莱柯 沪深300 相关研究报告 《费用率偏高业绩短期承压，静待后 周期业绩修复—公司信息更新报告》 -2024.11.3 《新品储备充足持续成长，猪价高位 运行静待业绩修复—公司信息更新报 告》-2024.8.30 《业绩有望随猪周期反转修复，高分 红彰显投资价值—公司信息更新报 告》-2024.4.26 普莱柯（603566.SH） 2025 年 04 月 26 日 投资评级：买入（维持） 公司发布 2024 年年报及 2025 年一季报，2024 年公司营收 10.43 亿元(-16.77% ...

证券研究报告 普莱柯 (603566 CH) 本报告来源于"慧博投研",请勿外传! 禽苗、化药销售向好,Q1 盈利超预期 | 华泰研究 | 年报点评 | | --- | --- | | 2025年4月25日 中国内地 | 农林牧渔 | 资料来源:公司公告、华泰研究预测 | 投资评级(维持): | 头人 | | --- | --- | | 目标价(人民币): | 15.25 | | 研究员 | 樊俊豪 | | SAC No. S0570524050001 | fanjunhao@htsc.com | | SFC No. BDO986 | +(852) 3658 6000 | | 研究员 | 熊承慧,PhD | | SAC No. S0570522120004 | xiongchenghui@htsc.com | | SFC No. BPK020 | +(86) 10 6321 1166 | | 研究员 | 张正芳 | | SAC No. S0570524070009 zhangzhengfang@htsc.com | | | | +(86) 10 6321 1166 | 普莱柯发布 2024 年报及 2025 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 5、公司将依据相关规定，及时做好信息披露工作，并在定期报告中披露报告期内使用闲置资金进行现 金管理的具体情况。 公司本次使用部分闲置自有资金进行现金管理，仅投资于安全性高、流动性好的短期保本或稳健型理财 产品，投资风险可控；但金融市场受宏观经济、市场波动的影响，不排除投资收益具有一定的不可预期 性。敬请广大投资者谨慎决策，注意防范投资风险。 五、决策程序的履行情况 公司于2025年4月24日召开第五届董事会第十八次会议、第五届监事会第十二次会议，分别审议通过了 《关于使用部分闲置自有资金进行现金管理的议案》；同意自股东大会审议通过之日起12个月内，在保 证正常经营所需流动资金的情况下，使用不超过人民币6.5亿元暂时闲置自有资金进行现金管理；在上 述额度内，该类资金可以单笔或分笔进行单次或累计滚动不超过一年期的现金管理，并授权由公司法定 代表人或其授权人员行使投资决策职责和具体实施。 该议案尚需提交股东大会审议通过。 特此公告 三、对公司的影响 1、公司本次使用部分闲置自有资金进行现金管理，是在确保公司日常经营和资金安全的前提下实施 的，不影响日常经营资金的正常 ...

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., has released its 2024 annual report summary, highlighting its financial performance, profit distribution plan, and the current state of the veterinary medicine industry in China. Company Overview - Pulaike operates in the veterinary medicine manufacturing sector, providing essential support for high-quality development in livestock farming and pet health management [5]. - The company focuses on the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine, with over 80 biological products and 200 chemical drugs in its portfolio [17][18]. Industry Situation Industry Scale - In 2023, China's veterinary medicine production enterprises achieved sales of 69.651 billion yuan, with a gross profit of 21.297 billion yuan. The industry has shown an overall upward trend over the past decade, with a compound annual growth rate of 6.16% [6]. Competitive Landscape - The industry consists of 1,620 veterinary medicine production enterprises, primarily medium and small-sized. Large enterprises account for 15.25% of biological product companies and 4.02% of chemical drug companies, indicating a stable industry concentration [7]. Development Trends - The veterinary medicine industry aims to provide high-quality products and services for livestock and pet owners. Companies with core competitiveness in technology innovation, product quality, market expansion, and comprehensive service capabilities will thrive in a highly competitive market [9]. Regulatory Policies - New regulations regarding veterinary drug registration and animal disease prevention have been introduced, aiming to enhance the authenticity and standardization of registration materials and improve disease control measures [10][11]. Financial Performance - For the fiscal year 2024, the company reported a net profit of 92.8065 million yuan, with a proposed cash dividend of 4 yuan per 10 shares, amounting to an estimated total distribution of 136.7677 million yuan [27][26]. Shareholder Information - The company has a total share capital of 346,062,273 shares, with 4,142,900 shares repurchased and not participating in the profit distribution [27][28]. Cash Management - The company plans to use up to 650 million yuan of idle funds for cash management, focusing on safe and liquid short-term investment products [34][35].

普莱柯生物工程股份有限公司 董事会审计委员会 2024 年度履职情况报告 普莱柯生物工程股份有限公司（以下简称"公司"）董事会审计委员会按照中国 证监会《上市公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》和公司相关治理制度的要求，本着客观、公正、独立的原则审议各项议 案，规范运作、科学决策。全体委员廉洁自律、勤勉尽责，充分履行了审查、监督 职能，为完善内部控制、提高财务报告质量发挥了重要作用。现就 2024 年度审计 委员会工作情况向董事会作如下报告： 一、审计委员会基本情况 2023 年 4 月 11 日，公司召开了第五届董事会第一次会议，审议通过了《关于 选举第五届董事会专门委员会组成人员的议案》，选举独立董事张宪胜先生（主任 委员）、独立董事王楚端先生、董事赵锐先生组成公司第五届董事会审计委员会， 其中主任委员由具有专业会计资格的独立董事张宪胜先生担任。 2024 年 1 月 3 日，公司召开了第五届董事会第八次会议，审议通过《关于调整 第五届董事会审计委员会委员的议案》，公司董事赵锐先生不再担任公司第五届董 事会审计委员会委员，选举副董事长秦德超先生担任第五届董事会审计委 ...